The above results collectively suggested that this FXR inhibitor, Z-GS, decreased the FXR/IL-6/IL-6ST/p-STAT3 axis and reduced FXRhigh NSCLC metastasis in mouse models in vivo. Here, STAT3 is linked to non-small cell lung carcinoma.